# Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy

> **NCT02423707** · PHASE2,PHASE3 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 110 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** ALK Alutard Birch and/or 5-grasses
- **DRUG:** ALK Diluent

## Key facts

- **NCT ID:** NCT02423707
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2015-11
- **Final completion:** 2017-12
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423707, "Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02423707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*